Scalper1 News
Gene-sequencing giant Illumina (ILMN) beat analysts’ Q2 earnings estimates Tuesday but missed on revenue, sending shares down 11% in after-hours trading. Illumina said income excluding one-time items amounted to 80 cents a share, up 41% from the year-earlier quarter and beating analysts’ consensus by 3 cents, according to Thomson Reuters. Revenue climbed 21% to $539 million, about $3 million short of consensus. That was the third straight quarter Scalper1 News
Scalper1 News